The present invention provides for a novel peptidic antagonist for the bradykinin B1 (BKB.sub.1) receptor having very good to excellent affinities and selectivity for the BKB.sub.1 receptor, in vitro and in vivo increase resistance to enzymatic degradation, superior pharmacokinetic properties, capability to significantly reduce microvascular leakage observed alongside diabetic-induced increase in vascular permeability, capability to significantly reduced the state of hyperalgesia alongside diabetes, capability to significantly reduce the infiltration of pro-inflammatory cells and general state of inflammation alongside allergic asthma.